The effects of IGF-1 treatment after hypoxic-ischemic brain injury in adult rats

J Cereb Blood Flow Metab. 1993 Jul;13(4):609-16. doi: 10.1038/jcbfm.1993.79.

Abstract

Intraventricular injection of insulin-like growth factor 1 (IGF-1) 2 h after hypoxic-ischemic injury reduces neuronal loss. To clarify the mode of action, we compared histological outcome between treatment groups in the following three studies: 0, 0.5, 5, and 50 micrograms IGF-1 given 2 h after injury; 0 and 20 micrograms IGF-1 given 1 h before; and 20 micrograms IGF-1 and insulin or vehicle alone given 2 h after. Unilateral hypoxic-ischemic injury was induced in adult rats by ligation of the right carotid and exposure to 6% O2 for 10 min. Histological outcome was evaluated in the cortex, striatum, and hippocampus 5 days later. Five to 50 micrograms IGF-1 reduced the incidence of infarction and neuronal loss in a dose-dependent manner in all regions (p < 0.05), and 50 micrograms reduced the infarction rate from 87 to 26% (p < 0.01). Pretreatment did not alter outcome. IGF-1 improved outcome compared with equimolar doses of insulin (p < 0.05) and did not affect systemic glucose concentrations or cortical temperature. The results indicate that the neuronal protective effects of IGF-1 are specific and are not mediated via insulin receptors, hypothermia, or hypoglycemic mechanisms. Centrally administered IGF-1 appears to provide worthwhile trophic support to cells within most cerebral structures after transient hypoxic-ischemic injury.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Body Temperature / drug effects
  • Brain / drug effects
  • Brain / physiopathology
  • Brain Ischemia / complications
  • Brain Ischemia / pathology*
  • Brain Ischemia / physiopathology
  • Cerebral Infarction / etiology
  • Cerebral Infarction / prevention & control
  • Dose-Response Relationship, Drug
  • Hypoxia, Brain / complications
  • Hypoxia, Brain / pathology*
  • Hypoxia, Brain / physiopathology
  • Male
  • Rats
  • Rats, Wistar
  • Somatomedins / administration & dosage
  • Somatomedins / pharmacology*
  • Time Factors

Substances

  • Somatomedins